Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.
Don't worry about a little selloff, says Jim Cramer. The data and earnings signal an improving economy.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.